Although not my favourite solution but it is still a positive note. If deal go through with cheaper cost of fund and more products can be introduced will have good impact on MBSB.
Still another 3 quarters to write down impairments and with 6 to 7% loan grow. A target of RM 2.00 is a fair target. We continue to hold and buy in weakness below RM 1.30.